Clinical Trial

Evaluation of Cirrhotic Cardiomyopathy by Cardiac MRI in Patients Waiting for Liver Transplant.

Study acronym: CARDIOFIBROCIR
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The aim of this multicenter prospective interventional pilot study is to describe the evolution of myocardial fibrosis in cirrhotic patients before and after liver transplantation (LT). Through multimodal analysis of myocardial function and architecture, and analysis of specific markers of inflammation, we aim to explore the following hypotheses: 1) systemic inflammation promotes myocardial fibrosis in cirrhotic patients and could be an early marker of cirrhotic cardiomyopathy; 2) LT allows resolution of myocardial fibrosis by preventing the bacterial translocation that favors the development of deleterious systemic inflammation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-03-18; most recent amendment 2026-07-20.
Status change: Not Yet Recruiting → Recruiting 2026-07-20
Trial Details
NCT Number NCT06327308
Lead Sponsor Centre Hospitalier Universitaire de Besancon
Conditions Cirrhosis, Registered on Transplant List
Enrollment 60 participants
Start Date 2025-03-11
Primary Completion 2027-03-11 (estimated)
Study Completion 2029-12-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-22